相似文献
1
Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Br J Pharmacol. 2006 Feb;147(4):360-70. doi: 10.1038/sj.bjp.0706601.
2
G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Br J Pharmacol. 2004 Nov;143(5):638-48. doi: 10.1038/sj.bjp.0705951. Epub 2004 Sep 27.
3
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors.
Can J Physiol Pharmacol. 2002 May;80(5):407-12. doi: 10.1139/y02-040.
4
N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors.
Neuropsychopharmacology. 2007 Apr;32(4):773-85. doi: 10.1038/sj.npp.1301152. Epub 2006 Jul 12.
5
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14.
6
Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Br J Pharmacol. 1997 Oct;122(3):401-8. doi: 10.1038/sj.bjp.0701357.
7
Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
J Comp Neurol. 1997 Oct 6;386(4):562-72. doi: 10.1002/(sici)1096-9861(19971006)386:4<562::aid-cne4>3.0.co;2-0.
8
Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
J Pharmacol Exp Ther. 2003 Jul;306(1):179-86. doi: 10.1124/jpet.103.050625. Epub 2003 Apr 3.
9
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
J Pharmacol Exp Ther. 1997 Aug;282(2):676-84.
10
In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
Neuroreport. 2001 Jun 13;12(8):1757-61. doi: 10.1097/00001756-200106130-00048.
引用本文的文献
1
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits.
Drugs. 2025 Feb;85(2):215-230. doi: 10.1007/s40265-024-02128-y. Epub 2025 Jan 28.
2
Morphine-Induced Elevation of Reactive Oxygen Species Attenuates Chemotherapy Efficacy in Diverse Cancer Cell Types.
Curr Mol Med. 2025;25(4):460-471. doi: 10.2174/0115665240314564241129044548.
3
Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch.
Front Pharmacol. 2021 Nov 16;12:773204. doi: 10.3389/fphar.2021.773204. eCollection 2021.
4
Comparative analysis of the effects of opioids in angiogenesis.
BMC Anesthesiol. 2021 Oct 26;21(1):257. doi: 10.1186/s12871-021-01475-7.
5
The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors.
Br J Pharmacol. 2012 Nov;167(6):1329-41. doi: 10.1111/j.1476-5381.2012.02078.x.
6
Molecular and genetic substrates linking stress and addiction.
Brain Res. 2010 Feb 16;1314:219-34. doi: 10.1016/j.brainres.2009.11.002. Epub 2009 Nov 10.
7
kappa-Opioid receptor signaling and brain reward function.
Brain Res Rev. 2009 Dec 11;62(1):127-46. doi: 10.1016/j.brainresrev.2009.09.008. Epub 2009 Oct 2.
8
Endogenous opiates and behavior: 2006.
Peptides. 2007 Dec;28(12):2435-513. doi: 10.1016/j.peptides.2007.09.002. Epub 2007 Sep 11.
9
Dynorphin and the pathophysiology of drug addiction.
Pharmacol Ther. 2007 Nov;116(2):306-21. doi: 10.1016/j.pharmthera.2007.06.011. Epub 2007 Jul 24.
10
Has the sun set on kappa3-opioid receptors?
Br J Pharmacol. 2006 Feb;147(4):349-50. doi: 10.1038/sj.bjp.0706603.
本文引用的文献
1
Autoradiography in opioid triple knockout mice reveals opioid and opioid receptor like binding of naloxone benzoylhydrazone.
Neuropharmacology. 2005 Feb;48(2):228-35. doi: 10.1016/j.neuropharm.2004.09.016. Epub 2004 Dec 8.
2
G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Br J Pharmacol. 2004 Nov;143(5):638-48. doi: 10.1038/sj.bjp.0705951. Epub 2004 Sep 27.
3
Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.
Br J Pharmacol. 2003 Sep;140(1):61-70. doi: 10.1038/sj.bjp.0705401. Epub 2003 Aug 11.
4
Involvement of glutamate and gamma-amino-butyric acid receptor systems on gastric acid secretion induced by activation of kappa-opioid receptors in the central nervous system in rats.
Br J Pharmacol. 2003 Mar;138(6):1049-58. doi: 10.1038/sj.bjp.0705082.
5
Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.
Br J Pharmacol. 2002 Dec;137(8):1355-61. doi: 10.1038/sj.bjp.0704998.
6
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors.
Can J Physiol Pharmacol. 2002 May;80(5):407-12. doi: 10.1139/y02-040.
7
The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.
Pharmacol Rev. 2001 Sep;53(3):381-415.
8
Differential antagonism by naloxone benzoylhydrazone of the activation of inward rectifying K+ channels by nociceptin and a mu-opioid in rat periaqueductal grey slices.
Naunyn Schmiedebergs Arch Pharmacol. 2001 Jun;363(6):583-9. doi: 10.1007/s002100100402.
9
Naloxone benzylhydrazone is a µ-selective opioid antagonist without kappa agonist effects in rhesus monkeys.
Behav Pharmacol. 1992 Apr;3(2):133-141.
10
Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells.
Neurosci Lett. 2001 Feb 23;299(3):173-6. doi: 10.1016/s0304-3940(01)01524-5.
Zotero 插件